Skip to main content
Erschienen in:

06.04.2019 | Original Article

Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior

verfasst von: Anna Gerbe, Melissa Alame, Olivier Dereure, Samia Gonzalez, Luc Durand, Ariane Tempier, Laura De Oliveira, Alicia Tourneret, Valérie Costes-Martineau, Valère Cacheux, Vanessa Szablewski

Erschienen in: Virchows Archiv | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Despite distinct clinical presentation and outcome, systemic, primary cutaneous, and breast implant-associated anaplastic large cell lymphomas (S-, PC-, BI-ALCL) ALK-negative (ALK−) show similar histopathological features including the presence of the “hallmark” cells with horseshoe-shaped nuclei and CD30 protein expression. The purpose was to better characterize these three entities using immunohistochemistry and FISH (Fluorescent in situ hybridization) to identify biomarkers differently expressed and that might be involved in their pathogenesis. Twenty-two S-ALCL ALK−, 13 PC-ALCL, and 2 BI-ALCL were included. Cases were tested for P53, P63, MUM1, MYC, GATA3, p-STAT3, PD1, and PDL1 protein expression and DUP22, TP53, TP63, MYC, and PDL1 chromosomal aberrations. As expected, S-ALCL ALK− patients had adverse outcome compare to PC and BI-ALCL. No difference was observed between the three groups concerning protein expression except for MUM1 that was significantly more frequently expressed in S-ALCL ALK− compared to PC-ALCL. In particular, constitutive activation of the STAT3 pathway and PDL1/PD1 immune-checkpoint expression was present in the three entities. TP53 deletion and PDL1 gene amplification were the commonest cytogenetic alterations and were present in the three entities. None of the studied biological parameters was associated with prognosis. Despite distinct clinical behavior, S-ALCL ALK−, PC-ALCL, and BI-ALCL share similar biological features. Larger series should be investigated with the current approach to determine more precisely the activity and the prognostic value of these biomarkers and pathways in each group.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol Off J Am Soc Clin Oncol 30:3452–3459 Published Online First: 30 July 2012. https://doi.org/10.1200/JCO.2011.41.0985 CrossRef Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol Off J Am Soc Clin Oncol 30:3452–3459 Published Online First: 30 July 2012. https://​doi.​org/​10.​1200/​JCO.​2011.​41.​0985 CrossRef
7.
Zurück zum Zitat van Dongen JJ, Langerak AW, Brüggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17:2257–2317. https://doi.org/10.1038/sj.leu.2403202 CrossRefPubMed van Dongen JJ, Langerak AW, Brüggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17:2257–2317. https://​doi.​org/​10.​1038/​sj.​leu.​2403202 CrossRefPubMed
8.
Zurück zum Zitat Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, Lamant L (2016) Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol Off J Eur Soc Med Oncol ESMO 27:306–314. https://doi.org/10.1093/annonc/mdv575 CrossRef Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, Lamant L (2016) Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol Off J Eur Soc Med Oncol ESMO 27:306–314. https://​doi.​org/​10.​1093/​annonc/​mdv575 CrossRef
9.
Zurück zum Zitat ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJLM (2003) ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 43:462–469CrossRefPubMed ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJLM (2003) ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 43:462–469CrossRefPubMed
10.
Zurück zum Zitat Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten W, Meijer CJ, Willemze R (2000) Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653–3661PubMed Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten W, Meijer CJ, Willemze R (2000) Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653–3661PubMed
14.
Zurück zum Zitat Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA Jr, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT Jr, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ (2014) Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol Off J Am Soc Clin Oncol 32:114–120. https://doi.org/10.1200/JCO.2013.52.7911 CrossRef Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA Jr, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT Jr, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ (2014) Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol Off J Am Soc Clin Oncol 32:114–120. https://​doi.​org/​10.​1200/​JCO.​2013.​52.​7911 CrossRef
15.
Zurück zum Zitat Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD, for the International Peripheral T-Cell Lymphoma Project (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma Project. Blood 111:5496–5504. https://doi.org/10.1182/blood-2008-01-134270 CrossRefPubMed Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD, for the International Peripheral T-Cell Lymphoma Project (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma Project. Blood 111:5496–5504. https://​doi.​org/​10.​1182/​blood-2008-01-134270 CrossRefPubMed
16.
Zurück zum Zitat Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473–1480. https://doi.org/10.1182/blood-2014-04-571091 CrossRefPubMedPubMedCentral Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473–1480. https://​doi.​org/​10.​1182/​blood-2014-04-571091 CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer Oxf Engl 1990 49:2869–2876. https://doi.org/10.1016/j.ejca.2013.04.029 CrossRef Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer Oxf Engl 1990 49:2869–2876. https://​doi.​org/​10.​1016/​j.​ejca.​2013.​04.​029 CrossRef
24.
Zurück zum Zitat Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G, European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies” (2015) Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27:516–532. https://doi.org/10.1016/j.ccell.2015.03.006 CrossRefPubMedPubMedCentral Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G, European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies” (2015) Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27:516–532. https://​doi.​org/​10.​1016/​j.​ccell.​2015.​03.​006 CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM, for the Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915–2923. https://doi.org/10.1182/blood-2013-11-536359 CrossRefPubMedPubMedCentral Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM, for the Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915–2923. https://​doi.​org/​10.​1182/​blood-2013-11-536359 CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NCT, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G (2015) Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood 125:124–132. https://doi.org/10.1182/blood-2014-08-594507 CrossRefPubMed Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NCT, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G (2015) Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood 125:124–132. https://​doi.​org/​10.​1182/​blood-2014-08-594507 CrossRefPubMed
32.
33.
Zurück zum Zitat Wada DA, Law ME, Hsi ED, DiCaudo DJ, Ma L, Lim MS, Souza A, Comfere NI, Weenig RH, Macon WR, Erickson LA, Özsan N, Ansell SM, Dogan A, Feldman AL (2011) Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol Off J U S Can Acad Pathol Inc 24:596–605. https://doi.org/10.1038/modpathol.2010.225 CrossRef Wada DA, Law ME, Hsi ED, DiCaudo DJ, Ma L, Lim MS, Souza A, Comfere NI, Weenig RH, Macon WR, Erickson LA, Özsan N, Ansell SM, Dogan A, Feldman AL (2011) Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol Off J U S Can Acad Pathol Inc 24:596–605. https://​doi.​org/​10.​1038/​modpathol.​2010.​225 CrossRef
36.
Zurück zum Zitat Gallo M, Cacheux V, Vincent L, Bret C, Tempier A, Guittard C, Macé A, Leventoux N, Costes V, Szablewski V (2016) Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14. Virchows Arch Int J Pathol 469:697–706. https://doi.org/10.1007/s00428-016-2016-8 CrossRef Gallo M, Cacheux V, Vincent L, Bret C, Tempier A, Guittard C, Macé A, Leventoux N, Costes V, Szablewski V (2016) Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14. Virchows Arch Int J Pathol 469:697–706. https://​doi.​org/​10.​1007/​s00428-016-2016-8 CrossRef
41.
Zurück zum Zitat Menguy S, Prochazkova-Carlotti M, Beylot-Barry M, Saltel F, Vergier B, Merlio JP, Pham-Ledard A (2017) PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type. Am J Surg Pathol 42:326–334 Published Online First: 3. https://doi.org/10.1097/PAS.0000000000000983 CrossRef Menguy S, Prochazkova-Carlotti M, Beylot-Barry M, Saltel F, Vergier B, Merlio JP, Pham-Ledard A (2017) PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type. Am J Surg Pathol 42:326–334 Published Online First: 3. https://​doi.​org/​10.​1097/​PAS.​0000000000000983​ CrossRef
42.
Zurück zum Zitat Four M, Cacheux V, Tempier A et al (2017) PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Hematol Oncol 35:487–496. Published Online First: 13 December 2016. https://doi.org/10.1002/hon.2375 CrossRefPubMed Four M, Cacheux V, Tempier A et al (2017) PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Hematol Oncol 35:487–496. Published Online First: 13 December 2016. https://​doi.​org/​10.​1002/​hon.​2375 CrossRefPubMed
43.
Zurück zum Zitat Twa DDW, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, Slack GW, Gunawardana J, Lim RS, McPherson AW, Kridel R, Telenius A, Scott DW, Savage KJ, Shah SP, Gascoyne RD, Steidl C (2014) Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123:2062–2065. https://doi.org/10.1182/blood-2013-10-535443 CrossRefPubMed Twa DDW, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, Slack GW, Gunawardana J, Lim RS, McPherson AW, Kridel R, Telenius A, Scott DW, Savage KJ, Shah SP, Gascoyne RD, Steidl C (2014) Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123:2062–2065. https://​doi.​org/​10.​1182/​blood-2013-10-535443 CrossRefPubMed
44.
Zurück zum Zitat Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869–881. https://doi.org/10.1182/blood-2015-10-673236 CrossRefPubMedPubMedCentral Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869–881. https://​doi.​org/​10.​1182/​blood-2015-10-673236 CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S (2016) Aberrant PD-L1 expression through 3’-UTR disruption in multiple cancers. Nature 534:402–406. https://doi.org/10.1038/nature18294 CrossRefPubMed Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S (2016) Aberrant PD-L1 expression through 3’-UTR disruption in multiple cancers. Nature 534:402–406. https://​doi.​org/​10.​1038/​nature18294 CrossRefPubMed
46.
Zurück zum Zitat Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ (2017) PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia 31:1633–1637. https://doi.org/10.1038/leu.2017.103 CrossRefPubMed Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ (2017) PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia 31:1633–1637. https://​doi.​org/​10.​1038/​leu.​2017.​103 CrossRefPubMed
49.
Metadaten
Titel
Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior
verfasst von
Anna Gerbe
Melissa Alame
Olivier Dereure
Samia Gonzalez
Luc Durand
Ariane Tempier
Laura De Oliveira
Alicia Tourneret
Valérie Costes-Martineau
Valère Cacheux
Vanessa Szablewski
Publikationsdatum
06.04.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 2/2019
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-019-02570-4

Neu im Fachgebiet Pathologie

Overview of a comparative analysis of microsatellite instability and standard mismatch repair protein-deficiency tests in a large cancer cohort

  • Hauptreferate: Hauptprogramm der DGP

A retrospective analysis was carried out based on a large cancer patient cohort of our institute ( n  = 1306; collected from 2018 to 2023). dMMR was tested by four IHC reactions (MLH1 and PMS2 or MSH2 and MSH 6). Further, parallel pentaplex …

Molekulare Testung bei mesenchymalen Neoplasien: Was, wann und wie testen?

Mit dem weit verbreiteten Einsatz diverser molekularer Methoden in der histopathologischen Routinediagnostik hat die Tumorklassifikation in den letzten beiden Jahrzehnten signifikante Fortschritte gemacht. Dabei wurden zum einen zahlreiche …

Reconstructing 3D histological structures using machine learning (artificial intelligence) algorithms

  • Hauptreferate: Hauptprogramm der DGP

Artificial intelligence (AI) has recently been applied to pathological and medical image analysis with high sensitivity and specificity [ 1 , 2 ], aiding in various dental diagnostic techniques. The use of AI in image annotation has enhanced the …

Key considerations when implementing new diagnostic technologies in routine practice

  • Hauptreferate: Arbeitsgemeinschaften der DGP

This review explores several key considerations that are critical for implementing new diagnostic technologies into routine practice. These elements will provide a comprehensive guide for navigating the complexities of integrating cutting-edge …